Kala Pharmaceuticals, Inc. (KALA)

Market Cap	26.30M
Revenue (ttm)	420,000
Net Income (ttm)	-8.64M
Shares Out	2.54M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,863
Open	10.59
Previous Close	10.69
Day's Range	10.29 - 10.82
52-Week Range	3.54 - 56.72
Beta	-1.50
Analysts	Strong Buy
Price Target	24.00 (+132.01%)
Earnings Date	Nov 7, 2023

About KALA

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA

Financial Performance

In 2022, KALA's revenue was $3.89 million, a decrease of -65.37% compared to the previous year's $11.24 million. Losses were -$44.82 million, -68.57% less than in 2021.

Analyst Forecast

According to one analyst, the rating for KALA stock is "Strong Buy" and the 12-month stock price forecast is $24.0.

Price Target

$24.0

(132.01% upside)

Analyst Consensus: Strong Buy